 Lipocine Inc. LPCN, a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the results of a pre-clinical study of LPCN 1144. LPCN 1144 is an oral prodrug of bioidentical testosterone testosterone undecanoate or TU. The pharmacological effect of LPCN 1144 was investigated in a non-genomic, five arm, 12-week high fat diet HFD-induced, rabbit animal model of NASH and hepatic fibrosis. 